Oncology

Digital health news update: Merger mania; advertising’s existential dillema

Walgreens is expanding its telehealth deal with MDLive to cover behavioral therapy virtual visits as part of a broader mental health offering. Fortune notes that it “gives Walgreens an important touchpoint with payers, providers and patients: drug adherence.” Fitbit CEO James Park told investors and analysts that the company is looking to go deeper on […]

Latin America scrambles to contain Zika virus

From relative obscurity, the Zika virus burst into global consciousness in early 2016 as the arbovirus spread rapidly across the Latin American region and threatens to hit the United States. In its wake, the Zika virus is leaving countries scrambling to stop it before more people become infected, with particular focus on pregnant women. Although […]

War on Cancer: A Unified Battle in the 21st Century

Nearly half a century after the inception of the National Cancer Act in 1971 and U.S. President Nixon’s declaration of “war on cancer” great progress in understanding cancer biology, developing new therapeutics and diagnostics, and improving patient access has been made; however, the incidence of cancer has been rising and efforts to reduce overall cancer […]

The Decision Resources Group Companies Are Now DRG

Introducing the new DRG Since its inception, Decision Resources Group (DRG) has been a premier provider of healthcare analytics, data, and insight products and services to the world’s leading pharma, biotech, and med tech companies. In an increasingly competitive and dynamic healthcare marketplace, the ability to access, synthesize and analyze data can make or break […]

Medical devices for the everyday consumer: in more places than you’d think

The medical device industry is pretty elusive?most people go about their everyday lives without really thinking about this industry churning away in the background. In fact, you might not have even thought of your hip implant or pacemaker being a cog in a much larger wheel of a very important industry. While big pharma is …

Is there anyone that does not love the PCSK9 inhibitors?

Everyone who knows anything about lipids and cardiovascular (CV) disease loves the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: dyslipidemia experts, giant pharma companies, and even humble analysts all recognize the excellent low-density lipoprotein cholesterol (LDL-C)-lowering efficacy, the high likelihood of real CV benefits, and the clean safety profile of the PCSK9 inhibitors ? they are …